SOLA owns the JUMP70 platform, a gene therapy that uses AAV to express JUMP70, a fusion protein capable of bringing disease-causing proteins into close proximity with the HSP70 protein, so that HSP could refold or induce degradation of the mis-folded aggregate protein which is a cause of neurodegenerative diseases. The lead pipeline, SOL-257, is being developed for ALS, a disease caused by the aggregation of TDP-43 protein.
Location: United States, Massachusetts, Natick
Employees: 11-50
Investors 2
| Date | Name | Website |
| 10.07.2026 | The Univer... | ut-ec.co.j... |
| 07.10.2021 | MP Healthc... | mp-healthc... |